FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 351:2035-2037 November 11, 2004 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Taylor, A. L. PubMed Citation

Are we moving into a new era of race-based therapeutics? The publication, in this issue of the Journal, of the African-American Heart Failure Trial (A-HeFT) (pages 2049–2057), a clinical trial of a medication intended for a single racial group, poses this awkward question. The study's most striking finding — that the addition of isosorbide dinitrate and hydralazine to conventional therapy for heart failure reduced relative one-year mortality by 43 percent among blacks — will provoke wide discussion. The trial's sponsor, NitroMed, which holds a patent on the fixed-dose combination of isosorbide dinitrate and hydralazine that was used, posits that heart . . . [Full Text of this Article]

Source Information

From the Georgetown University Law Center, Washington, D.C., and the Bloomberg School of Public Health, Johns Hopkins University, Baltimore.

This article has been cited by other articles:

• Singh, S. P. (2009). Shooting the messenger: the science and politics of ethnicity research. Br. J. Psychiatry 195: 1-2 [Abstract] [Full Text]  
• Henderson, G. E. (2008). Introducing Social and Ethical Perspectives on Gene--Environment Research. Sociological Methods Research 37: 251-276 [Abstract]  
• Epstein, S. (2008). The rise of 'recruitmentology': clinical research, racial knowledge, and the politics of inclusion and difference.. Social Studies of Science 38: 801-832 [Abstract]  
• Tucker, C. M., Ferdinand, L. A., Mirsu-Paun, A., Herman, K. C., Delgado-Romero, E., van den Berg, J. J., Jones, J. D. (2007). The Roles of Counseling Psychologists in Reducing Health Disparities. The Counseling Psychologist 35: 650-678 [Abstract]  
• Tilburt, J., Ford, J. G., Howerton, M. W., Gary, T. L., Lai, G. Y., Bolen, S., Baffi, C., Wilson, R. F., Tanpitukpongse, T. P., Powe, N. R., Bass, E. B., Sugarman, J. (2007). Applying justice in clinical trials for diverse populations. Clin Trials 4: 264-269 [Abstract]  
• Temple, R., Stockbridge, N. L. (2007). BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. ANN INTERN MED 146: 57-62 [Abstract] [Full Text]  
• Brody, H., Hunt, L. M. (2006). BiDil: Assessing a Race-Based Pharmaceutical. Ann Fam Med 4: 556-560 [Abstract] [Full Text]  
• Sterling, R., Henderson, G. E., Corbie-Smith, G. (2006). Public Willingness to Participate in and Public Opinions About Genetic Variation Research: A Review of the Literature. AJPH 96: 1971-1978 [Abstract] [Full Text]  
• Lillquist, E., Sullivan, C. A. (2006). Legal Regulation of the Use of Race in Medical Research. J Law Med Ethics 34: 535-551  
• Bloche, M. G. (2006). Race, Money and Medicines. J Law Med Ethics 34: 555-558  
• Ballard, R. A., Truog, W. E., Cnaan, A., Martin, R. J., Ballard, P. L., Merrill, J. D., Walsh, M. C., Durand, D. J., Mayock, D. E., Eichenwald, E. C., Null, D. R., Hudak, M. L., Puri, A. R., Golombek, S. G., Courtney, S. E., Stewart, D. L., Welty, S. E., Phibbs, R. H., Hibbs, A. M., Luan, X., Wadlinger, S. R., Asselin, J. M., Coburn, C. E., the NO CLD Study Group, (2006). Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.. NEJM 355: 343-353 [Abstract] [Full Text]  
• Whittle, J., Kressin, N. R., Peterson, E. D., Orner, M. B., Glickman, M., Mazzella, M., Petersen, L. A. (2006). Racial Differences in Prevalence of Coronary Obstructions Among Men With Positive Nuclear Imaging Studies. J Am Coll Cardiol 47: 2034-2041 [Abstract] [Full Text]  
• Jawa, A., Nachimuthu, S., Pendergrass, M., Asnani, S., Fonseca, V. (2006). Impaired Vascular Reactivity in African-American Patients with Type 2 Diabetes Mellitus and Microalbuminuria or Proteinuria Despite Angiotensin-Converting Enzyme Inhibitor Therapy. J. Clin. Endocrinol. Metab. 91: 31-35 [Abstract] [Full Text]  
• Prathikanti, S., Weinberger, D. R. (2005). Psychiatric genetics - the new era: genetic research and some clinical implications. Br Med Bull 73-74: 107-122 [Abstract] [Full Text]  
• Angus, D. C., Linde-Zwirble, W. T., Tam, S. W., Ghali, J. K., Sabolinski, M. L., Villagra, V. G., Winkelmayer, W. C., Worcel, M., for the African-American Heart Failure Trial (A-He, (2005). Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure. Circulation 112: 3745-3753 [Abstract] [Full Text]  
• Krieger, N. (2005). Stormy Weather: Race, Gene Expression, and the Science of Health Disparities. AJPH 95: 2155-2160 [Abstract] [Full Text]  
• Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., Schulman, K. A. (2005). Implications of Pharmacogenomics for Drug Development and Clinical Practice. Arch Intern Med 165: 2331-2336 [Abstract] [Full Text]  
• Martin, R. J., Walsh, M. C. (2005). Inhaled Nitric Oxide for Preterm Infants -- Who Benefits?. NEJM 353: 82-84 [Full Text]  
• (2004). An Old Drug Combination Tested in Black Patients. Journal Watch Cardiology 2004: 1-1 [Full Text]  
• (2004). Isosorbide Dinitrate plus Hydralazine for Blacks with Heart Failure. JWatch General 2004: 1-1 [Full Text]